The authors performed this analysis to examine whether the enhanced clopidogrel responsiveness in current smokers is maintained after adjusting the influence of hemoglobin on VerifyNow P2Y12 reaction unit (PRU).
clopidogrel, cigarette smoking is reported to be associated with enhanced clopidogrel responsiveness (5) (6) (7) . The reason for this phenomenon is not clear, although several mechanisms have been suggested, including those regarding cytochrome P450 enzyme system.
It is reported consistently that higher hemoglobin or hematocrit levels are associated with a lower VerifyNow (Accumetrics, San Diego, California) P2Y12 reaction unit (PRU) and vice versa (8) (9) (10) (11) . Furthermore, this association between hemoglobin (or hematocrit) and PRU is thought to be a laboratory error rather than true difference in platelet reactivity (8, 9) .
Meanwhile, smoking is associated with increased levels of hemoglobin and hematocrit (12) (13) (14) . It is not clear whether smoking is associated with a lower PRU value due to altered pharmacodynamics of clopidogrel in smoking patients or its association with increased hemoglobin level, which would lead to a lower PRU value. Gremmel et al. (15) assay to measure platelet reactivity (6, 7, (16) (17) (18) (19) (20) , the association among PRU, smoking, and hemoglobin should be elucidated. We conducted this analysis to evaluate whether the relationship between smoking and enhanced clopidogrel responsiveness is a true in vivo phenomenon that is independent of hemoglobin level or is just a laboratory error due to the confounding effect of hemoglobin. Before undergoing PCI, patients were given 100 mg aspirin and 75 mg clopidogrel daily for at least 7 days.
Loading doses of aspirin (300 mg) and clopidogrel (300 to 600 mg) were given to patients who had not taken them before. After PCI, aspirin and clopidogrel were administered for at least 6 months. If random- Blood samples for platelet function test were taken from each patient after PCI and before discharge. 
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In SNUBH cohort, platelet function was also measured with MEA (Multiplate, Dynabyte, Munich, Germany), a whole blood impedance aggregometer.
Adenosine diphosphate (ADP)-induced platelet aggregation in whole blood was assessed as previously described in other studies (26) . In SNUBH cohort, Kim et al.
A U G U S T 2 2 , 2 0 1 6 : 1 6 8 0 -9 0 Englewood, NJ). All significance tests were 2-tailed, and p < 0.05 was considered significant. 137 patients were enrolled in HOST-ASSURE trial and these patients were excluded from the combined cohort). After removing 1,080 cilostazol users, the final combined cohort consisted of 1,314 patients ( Figure 1 ).
RESULTS
Baseline characteristics of the final combined cohort are summarized in Table 2 . 14.4 AE 1.5; p < 0.001; Figure 2D ) compared with nonsmokers. In Kaplan-Meier survival curve analysis, there was no difference in the incidence rate of MACE between nonsmokers and current smokers (3.2% vs.
1.9%; log-rank p ¼ 0.949) (Online Figure 1) . Cumulative incidence of definite and probable stent thrombosis and bleeding events also did not differ between nonsmokers and current smokers (Online Table 1 ).
HEMOGLOBIN-ADJUSTED PRU BETWEEN NONSMOKERS
AND CURRENT SMOKERS. Because PRU and hemoglobin showed a significant inverse correlation and current smokers had a significantly higher hemoglobin 
A U G U S T 2 2 , 2 0 1 6 : 1 6 8 0 -9 0 Figure 3B ).
The results of separate cohorts are presented in Online p ¼ 0.078) ( Figure 3E ). Multivariate linear regression analysis also revealed that smoking status is not associated with PRU, whereas age, sex, and hemoglobin are significantly associated with PRU (Online Table 3 ).
Variance inflation factors indicate that there is no significant multicollinearity.
In a subgroup of patients, hematocrit was also available in addition to hemoglobin (n ¼ 981).
Hematocrit also showed an inverse association with PRU. The association between smoking status and PRU was lost after adjusting: 1) hematocrit alone and 2) age, sex, and hematocrit simultaneously (Online Figure 6C) . In general, the observed difference in PRU was in accordance with the estimated difference in PRU, which means that the observed differences in PRU among never smokers, former smokers, and current smokers can largely be explained by hemoglobin differences of each group. Whiskers denote 95% confidence intervals. Abbreviations as in Figure 2 .
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DISCUSSION
In this study, we found that cigarette smoking does not improve clopidogrel responsiveness when PRU is adjusted for hemoglobin. Because PRU, hemoglobin, and smoking status are closely associated, hemoglobin should be considered as a covariate when evaluating the influence of smoking on clopidogrel Meta-analyses using random effects model were performed to calculate the effect of smoking on raw PRU (A), hemoglobin-adjusted PRU (B), and hemoglobin, sex, ageadjusted PRU (C). CI ¼ confidence interval; other abbreviations as in Figures 1 to 3 . Figures 2 and 3 .
responsiveness. To the best of our knowledge, this is the first study that took hemoglobin level into account before defining the relationship between smoking status and clopidogrel responsiveness.
CURRENT CONCEPT OF THE SMOKERS' PARADOX.
In several large scale clinical trials, nonsmokers did not benefit from clopidogrel therapy, whereas smokers showed a significant reduction in primary outcome endpoints related to clopidogrel treatment (5, 16, 30) . This phenomenon is called the smokers' paradox and enhanced clopidogrel responsiveness in smokers is suggested as one of the underlying mechanisms. Clopidogrel, a prodrug, needs to be converted to active metabolite by cytochrome P450 enzyme system to bind to P2Y 12 ADP receptor (6, 16) . It is believed that the induction of cytochrome P450 1A2 and 2B6 by cigarette smoking is responsible for enhanced clopidogrel responsiveness in smokers (6, 7, 16) paradox is valid only when VerifyNow P2Y12 assay is used for platelet function test.
ROLE OF HEMOGLOBIN AS A CONFOUNDING FACTOR.
Prasugrel is a third-generation thienopyridine P2Y 12 receptor inhibitor and the pharmacodynamics and metabolism of prasugrel is not influenced by smoking status (16, 28) . Therefore, it is inferable that there would be no difference in PRU between prasugrel- Kim et al.
Smoking Does Not Improve Clopidogrel Response A U G U S T 2 2 , 2 0 1 6 : 1 6 8 0 -9 0 PRU value at multiple follow-up timepoints, regardless of whether they were allocated to prasugrel arm or clopidogrel arm (28) . Regarding these data, it is possible that the induction of cytochrome P450 enzyme system by smoking is not the cause of the observed low PRU in current smokers taking clopidogrel.
Previous reports (8) (9) (10) (11) Therefore, it is possible that hemoglobin concentration might have an influence on PRU value that is unrelated to intrinsic platelet reactivity. However, further investigation is needed to clarify the underlying mechanism.
The present study also confirms the inverse association between PRU and hemoglobin. It is also well-known that current smokers have higher hemoglobin level than nonsmokers. Because the association between PRU and hemoglobin is reported to be a laboratory artifact rather than a true difference in platelet reactivity (8, 9) , differences in the hemoglobin level between current smokers and nonsmokers should be adjusted before comparing PRU value. Our general linear model (analysis of covariance) revealed that there is no difference in PRU between nonsmokers and current smokers after adjusting hemoglobin as a covariate. The regression coefficient between PRU and hemoglobin was -21.4
and the observed difference in PRU between nonsmokers and current smokers was -17.9, which means that the difference in PRU between nonsmokers and current smokers can largely be explained by the confounding effect of hemoglobin.
In the TRILOGY ACS trial, although unadjusted PRU was associated with adverse cardiac events, this association was lost after adjusting multiple clinical variables (32). However, hemoglobin was not adjusted in the study. It would be an area of future research to explore the impact of hemoglobin adjustment on the predictive value of PRU.
STUDY LIMITATIONS. First, this study is a retrospective analysis of previously constructed cohorts.
Second, smoking status was recorded based on selfreport rather than using biomarkers such as urinary cotinine levels. We cannot exclude the possibility of underreporting.
CONCLUSIONS
There was no difference in PRU between nonsmokers and current smokers after adjusting hemoglobin.
Our data suggest that cigarette smoking does not improve clopidogrel responsiveness. Kim et al.
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